Spinal cord stimulation is a well-established treatment for chronic intractable pain of the trunk and/or limbs; however, low back pain (LBP) is difficult to treat using traditional SCS. Differential Target Multiplexed spinal cord stimulation (DTM SCS) is an advanced approach inspired from animal studies demonstrating improved pain-related behavior and pain-relevant biological processes.
To compare the effectiveness of DTM SCS and traditional SCS in treating chronic LBP and leg pain METHODS: This prospective, post-market randomized controlled trial compared DTM SCS to traditional SCS in patients with chronic low back and leg pain. Primary endpoint was LBP responder rate (percentage of subjects with ≥50% relief) at three months. Non-inferiority and superiority were assessed. Other outcomes included mean change in back and leg pain, responder rates, disability, global health, satisfaction, and safety profile throughout the 12-month follow up.
One hundred and twenty-eight subjects were randomized across 12 centers (67 DTM SCS, 61 traditional SCS). Of the 94 patients implanted, 46 subjects in each group completed the 3-month assessment. LBP responder rate of 80.1% with DTM SCS was superior to 51.2% with traditional SCS (P = 0.0010). Mean LBP reduction (5.36 cm) with DTM SCS was greater than reduction (3.37 cm) with traditional SCS (P < 0.0001). These results were sustained at 6 months, and 12 months. Safety profiles were similar between treatment groups.
Superiority of DTM SCS compared with traditional SCS for chronic LBP was demonstrated. Clinical improvements provided by DTM SCS were sustained over 12 months and are expected to significantly impact the management of chronic LBP.

This article is protected by copyright. All rights reserved.